STAT+: Roche two-armed antibody posts strong tumor responses in lymphoma study, rivaling CAR-T therapy
An off-the-shelf bispecific antibody developed by Roche induced high and durable response rates in patients…
Category: biotechnology
STAT+: Patients with rare blood disorder benefit from Bluebird gene therapy while denied access in Europe
People with severe beta-thalassemia who live in Europe have been denied access to Bluebird Bio’s…
STAT+: Gilead, Bristol jaw over the superiority of rival CAR-T treatments for blood cancer
Competing, bespoke CAR-T cell therapies from Gilead Sciences and Bristol Myers Squibb have each demonstrated…
Listen: Biogen, Biogen, Biogen, with a dash of Omicron
How did the Aduhelm debacle push Biogen to the brink? And what’s the latest on…
STAT+: At biotech venture capital firms, collecting ‘consulting fees’ from startups has become widespread
Some of the biggest names in biotech venture capital have charged their startups millions of…
STAT+: Biogen’s reckoning: How the Aduhelm debacle pushed a troubled company and its fractured leadership to the brink
The shocking revelation came in a Saturday afternoon email, restricted to a tight circle of…
STAT+: Flagship to launch a new startup focused on neurodegenerative conditions, including Parkinson’s
Flagship Pioneering is gearing up to launch a new company that seems to be developing…
STAT+: Acadia drug meets endpoints for treating Rett syndrome, a rare neurological disease
An experimental drug being developed by Acadia Pharmaceuticals improved the symptoms of women and girls…
STAT+: Stoke Therapeutics drug, targeting genetic cause of childhood epilepsy, reduces seizure activity
An experimental drug from Stoke Therapeutics reduced the frequency of convulsive seizures in children with…
STAT+: Liquid biopsies could help screen for countless cancers. But who should get them?
By the time cancer is discovered, it’s often too late to change its course. Close…
STAT+: In a medical first, Vertex drug successfully targets the underlying cause of a genetic kidney disease
An experimental pill from Vertex Pharmaceuticals reduced levels of a damaging urine protein by nearly…
.jpg)
STAT+: Immunogen study achieves primary goal of shrinking tumors in patients with ovarian cancer
An antibody treatment that delivers a targeted dose of chemotherapy directly to cancer cells shrank…
STAT+: Alnylam’s new CEO hopes appointment inspires underrepresented groups
Before she accepted a recent offer to become chief executive of Alnylam Pharmaceuticals, Yvonne Greenstreet…
STAT+: ‘Start at the top’: Women in biotech on how to break down barriers in the industry
Agnieszka Czechowicz remembers what the Magenta Therapeutics website looked like before the biotech startup went…
STAT+: 4 food allergy immunotherapy companies to watch
More and more children are developing food allergies — and biotech companies are springing up…
STAT+: A VC explains why he sees a golden age in health care innovation
One sign you’re living through a golden age is that there’s a lot of gold…
FDA approves first drug for genetic cause of dwarfism
The Food and Drug Administration approved the first treatment for the most common cause of…
STAT+: Watch: Experts challenge Eli Lilly exec on effectiveness of Alzheimer’s drug
Months after the Food and Drug Administration approved Biogen’s Alzheimer’s drug Aduhelm, Eli Lilly hopes…
Listen: Biogen’s scientific succession & Michael Osterholm on pandemic Thanksgiving
Are we in for another winter surge? Has Biogen bottomed out? And can Covid-19 pills…
‘Growing a chair is easy’ and other words of wisdom from the audacious George Church
George Church, the larger-than-life Harvard biologist who pioneered both DNA sequencing and gene editing, is…
STAT+: Generate Biomedicines raises $370m and plans to increase workforce sixfold
Cambridge biotech Generate Biomedicines said Thursday it has raised $370 million in venture capital from…
STAT+: Gilead licenses cancer drugs from Arcus in potentially lucrative but risky bet on its cancer business
Gilead Sciences said Thursday that it has exercised an option to license four cancer drugs…
STAT+: Set to retire, Alnylam’s Maraganore reflects on his successor and his next steps
John Maraganore’s decision to step down as Alnylam Pharmaceuticals’ CEO after almost 20 years came…
STAT+: European regulators signal Biogen’s new Alzheimer’s therapy is unlikely to win approval
A panel of European drug reviewers notified Biogen that its Alzheimer’s treatment Aduhelm is unlikely…
STAT+: Startup Spotlight: Rectify is hoping it can mend broken ABC transporters, starting in the liver
A former Vertex scientist is setting his sights on an entire family of transporter proteins…
STAT+: ‘Quite puzzling’ results in Alzheimer’s study cloud future of tau-targeting antibody treatment
New clinical trial results may temper early hope for an experimental Genentech treatment that targets…
STAT+: More lung cancer patients see tumor responses with Mirati’s KRAS combination treatment
Mirati Therapeutics said Monday that more than 60% of patients with lung cancer showed confirmed…
STAT+: Moderna millionaires and the double-edged sword of stock market riches
In just a few years, Moderna went from stock market dud to moonshot, a prime example…
Listen: Moderna’s setback, the saga of drug pricing reform & a CEO’s next act
Is drug pricing reform actually happening? Why was Moderna’s stock down? And what’s next for…
STAT+: CAR-T therapies from Bristol, Gilead superior to standard treatment in blood cancer, studies show
Administering bespoke CAR-T cell therapies from Bristol Myers Squibb or Gilead Sciences provides greater benefit…
STAT+: Alzheimer’s conference preview: Aduhelm debate persists, while field grapples with new targets and directions
When physicians and scientists involved in Alzheimer’s disease gather in Boston next week for an…
STAT+: Moderna, making billions from its vaccine, bets on a genome-editing startup
Moderna, flush with cash thanks to its blockbuster Covid-19 vaccine, made waves back in August…
STAT+: With two new insurance partnerships, EQRx takes its first steps toward lowering drug prices. But how big are those steps?
EQRx — the buzzy biotech company with a lofty mission of making far less expensive…
STAT+: Centessa drug shows early promise for inherited lung disease, but liver safety issue seen in small study
An experimental “corrector” drug from Centessa Pharmaceuticals normalized the levels of a target protein in…
STAT+: Pharmalittle: Pelosi tries last-ditch drug pricing proposal; Merck sees up to $7B in Covid pill sales in 2022
And so, another working week will soon draw to a close. Not a moment too…
Listen: Vaccines for kids, inside Operation Warp Speed, & a big biotech resignation
Can the FDA be too transparent? Who deserves credit for Operation Warp Speed? And when…
STAT+: Alnylam’s longtime CEO to depart, new leader named
John Maraganore, who has been the chief executive of Alnylam for nearly 19 years, is…
Virtual Event: Bispecifics: the next weapon against cancer
Editor’s note: A livestream of the conversation will be embedded below at 2 p.m. ET….
STAT+: Rafael Pharma drug fails to prolong survival of patients with pancreatic cancer in large study
Rafael Pharmaceuticals said Thursday that its experimental treatment for pancreatic cancer failed to prolong the…
STAT+: Be careful who you sue: CytoDyn knowingly submitted an incomplete drug application to FDA, new documents show
CytoDyn and its CEO Nader Pourhassan have known the company’s long-delayed HIV drug was in…
Public-private partnership launched to accelerate gene therapies for rare diseases
The National Institutes of Health and U.S. Food and Drug Administration unveiled a public-private partnership…
STAT+: As scientific labs replace offices, pushback is mounting from wary neighbors
The rapid growth of biotech labs in Greater Boston might end up saving the region’s…
STAT+: 6 things to know before the readout of Rafael Pharma’s pancreatic cancer drug study
Pancreatic cancer is hard to detect early and notoriously resistant to treatment, making it the…
STAT+: Cortexyme’s bacteria-fighting Alzheimer’s drug fails primary goal, but company sees a path forward
A novel approach to treating Alzheimer’s disease failed to preserve memory and function in a…
STAT+: Licensing biotech breakthroughs is a contentious, painful slog. Can the process be fixed?
Students, employees, and professors at a research institution generally pledge that in the event they…
STAT+: Eight years after a landmark Supreme Court ruling on DNA ownership, its ramifications are becoming clearer
Today, if you want to know what scary family health secrets lay buried in your…
Athira chief executive resigns as company confirms she altered research
The chief executive of biotech Athira Pharma has permanently left the company after papers she…
Listen: Inside the vaccine race, how a Covid pill failed, & Biogen’s troubled launch
Is Moderna misunderstood? Can Biogen turn a profit in Alzheimer’s disease? And what went wrong…
STAT+: Pharmalittle: WHO hopes to buy Covid treatments for $10 a course; Sinema is a big obstacle to drug pricing reform
Rise and shine, another busy day is on the way. However, this is also shaping…
STAT+: An FDA rejection derails Omeros, exposing the empty promises of its CEO
It’s remarkable to watch Omeros CEO Greg Demopulos and his executive team dissolve into a…